What is the Cost of Diagnosis and Management of Drug Resistant Tuberculosis in South Africa?
Open Access
- 18 January 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (1), e54587
- https://doi.org/10.1371/journal.pone.0054587
Abstract
Drug-resistant tuberculosis (DR-TB) is undermining TB control in South Africa. However, there are hardly any data about the cost of treating DR-TB in high burden settings despite such information being quintessential for the rational planning and allocation of resources by policy-makers, and to inform future cost-effectiveness analyses. We analysed the comparative 2011 United States dollar ($) cost of diagnosis and treatment of drug sensitive TB (DS-TB), MDR-TB and XDR-TB, based on National South African TB guidelines, from the perspective of the National TB Program using published clinical outcome data. Assuming adherence to national DR-TB management guidelines, the per patient cost of XDR-TB was $26,392, four times greater than MDR-TB ($6772), and 103 times greater than drug-sensitive TB ($257). Despite DR-TB comprising only 2.2% of the case burden, it consumed ∼32% of the total estimated 2011 national TB budget of US $218 million. 45% and 25% of the DR-TB costs were attributed to anti-TB drugs and hospitalization, respectively. XDR-TB consumed 28% of the total DR-TB diagnosis and treatment costs. Laboratory testing and anti-TB drugs comprised the majority (71%) of MDR-TB costs while hospitalization and anti-TB drug costs comprised the majority (92%) of XDR-TB costs. A decentralized XDR-TB treatment programme could potentially reduce costs by $6930 (26%) per case and reduce the total amount spent on DR-TB by ∼7%. Although DR-TB forms a very small proportion of the total case burden it consumes a disproportionate and substantial amount of South Africa’s total annual TB budget. These data inform rational resource allocation and selection of management strategies for DR-TB in high burden settings.This publication has 30 references indexed in Scilit:
- The Impact and Cost of Scaling up GeneXpert MTB/RIF in South AfricaPLOS ONE, 2012
- Outcomes of Multi-Drug Resistant Tuberculosis (MDR-TB) among a Cohort of South African Patients with High HIV PrevalencePLOS ONE, 2011
- Evaluation of the Xpert MTB/RIF Assay for the Diagnosis of Pulmonary Tuberculosis in a High HIV Prevalence SettingAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Culture Conversion Among HIV Co-Infected Multidrug-Resistant Tuberculosis Patients in Tugela Ferry, South AfricaPLOS ONE, 2011
- Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysisBMC Pulmonary Medicine, 2010
- Emergence of Increased Resistance and Extensively Drug-Resistant Tuberculosis Despite Treatment Adherence, South AfricaEmerging Infectious Diseases, 2010
- Early Outcomes of MDR-TB Treatment in a High HIV-Prevalence Setting in Southern AfricaPLOS ONE, 2009
- Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: prospective observational studyBritish Journal of Clinical Pharmacology, 2007
- Feasibility and Cost-Effectiveness of Treating Multidrug-Resistant Tuberculosis: A Cohort Study in the PhilippinesPLoS Medicine, 2006
- Cost-Effectiveness of Treating Multidrug-Resistant TuberculosisPLoS Medicine, 2006